Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law

Humacyte, Inc.

Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).
Stockholders nominating directors must state intent to solicit proxies and provide evidence of compliance upon request.
Company may disregard proxies/votes if nominating stockholder fails to meet Rule 14a-19 requirements.
Bylaws updated for Delaware law: clarify virtual meeting adjournment procedures, eliminate stockholder list inspection requirement.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Humacyte, Inc.: The board of directors approved amended and restated bylaws, effective immediately (effective 2022-12-08).

Change: bylaw amendment
Effective: 2022-12-08

Exact text from the filing

On December 8, 2022, the board of directors of Humacyte, Inc. (the “Company”) approved amended and restated by laws, which became effective the same day.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-22-000195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.